BioCentury
ARTICLE | Product Development

BioNTech, Pfizer vaccine yields highest titers to date, but benchmark itself remains an open question

BioNTech, Pfizer unveil Phase I/II data from first of four COVID-19 vaccine candidates

July 2, 2020 1:35 AM UTC

BioNTech and Pfizer have unveiled early clinical data from the first of four COVID-19 vaccine candidates, becoming the first to disclose neutralizing antibody titers that surpass FDA’s recommended titer of 160 for convalescent plasma.

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) acknowledged that the level of immunity required for protection against SARS-CoV-2 infection and how much antibodies vs. T cells mediate immunity in the disease remain open questions even as industry has primarily focused on neutralizing antibodies as the key benchmark for COVID-19 vaccines ...

BCIQ Company Profiles

BioNTech SE

Pfizer Inc.